Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.

Fong CY, Grigoriadis G, Hocking J, Coutsouvelis J, Muirhead J, Campbell P, Paul E, Walker P, Avery S, Patil S, Spencer A, Schwarer A, Wei A.

Leuk Lymphoma. 2013 Feb;54(2):336-41. doi: 10.3109/10428194.2012.713479. Epub 2012 Sep 8.

PMID:
22812445
2.

Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.

Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, Dipersio JF, Vij R.

Am J Hematol. 2009 Nov;84(11):733-7. doi: 10.1002/ajh.21545.

3.

Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.

Hänel M, Friedrichsen K, Hänel A, Herbst R, Morgner A, Neser S, Nicklisch M, Teich M, Ehninger G, Fiedler F.

Onkologie. 2001 Aug;24(4):356-60.

PMID:
11574763
4.

Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.

Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK, Hochhaus A, Niederwieser D, Sayer HG.

J Cancer Res Clin Oncol. 2016 Jan;142(1):317-24. doi: 10.1007/s00432-015-2050-y. Epub 2015 Sep 30.

PMID:
26424692
5.

FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.

Eom KS, Min WS, Kim HJ, Cho BS, Choi SM, Lee DG, Lee S, Min CK, Kim YJ, Cho SG, Lee JW, Kim CC.

Med Oncol. 2011 Dec;28 Suppl 1:S462-70. doi: 10.1007/s12032-010-9653-6. Epub 2010 Aug 17.

PMID:
20714942
6.
7.

Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.

Tavil B, Aytac S, Balci YI, Unal S, Kuskonmaz B, Yetgin S, Gurgey A, Tuncer M, Gumruk F, Uckan D, Cetin M.

Pediatr Hematol Oncol. 2010 Oct;27(7):517-28. doi: 10.3109/08880018.2010.493578.

PMID:
20677923
8.

Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.

Carella AM, Cascavilla N, Greco MM, Melillo L, Sajeva MR, Ladogana S, D'Arena G, Perla G, Carotenuto M.

Leuk Lymphoma. 2001 Jan;40(3-4):295-303.

PMID:
11426551
9.

Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

Tavernier E, Le QH, Elhamri M, Thomas X.

Leuk Res. 2003 Mar;27(3):205-14.

PMID:
12537972
10.

De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).

Ferrara F, Palmieri S, Pocali B, Pollio F, Viola A, Annunziata S, Sebastio L, Schiavone EM, Mele G, Gianfaldoni G, Leoni F.

Eur J Haematol. 2002 Apr;68(4):203-9.

PMID:
12071935
11.

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation.

Ferrara F, Melillo L, Montillo M, Leoni F, Pinto A, Mele G, Mirto S.

Ann Hematol. 1999 Aug;78(8):380-4.

PMID:
10460353
12.

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.

De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.

Ann Hematol. 2014 Dec;93(12):2011-8. doi: 10.1007/s00277-014-2143-8. Epub 2014 Jul 4.

PMID:
24989345
13.

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.

Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.

Turk J Pediatr. 2000 Jul-Sep;42(3):198-204.

PMID:
11105617
14.

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.

Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F.

Am J Hematol. 1998 Jun;58(2):105-9.

15.

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.

Haematologica. 2007 Mar;92(3):389-96.

16.

The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.

Lee SR, Yang DH, Ahn JS, Kim YK, Lee JJ, Choi YJ, Shin HJ, Chung JS, Cho YY, Chae YS, Kim JG, Sohn SK, Kim HJ.

J Korean Med Sci. 2009 Jun;24(3):498-503. doi: 10.3346/jkms.2009.24.3.498. Epub 2009 Jun 15.

17.

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.

Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.

Ann Hematol. 2004 Aug;83(8):498-503. Epub 2004 May 20.

PMID:
15156346
19.

FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.

Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V.

Ann Hematol. 2005 Nov;84(12):792-5. Epub 2005 Nov 12.

PMID:
16047203
20.

Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.

Ferrara F, Izzo T, Criscuolo C, Riccardi C, Celentano M, Mele G.

Am J Hematol. 2010 Sep;85(9):687-90. doi: 10.1002/ajh.21791.

Items per page

Supplemental Content

Write to the Help Desk